<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547830</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2018-02</org_study_id>
    <nct_id>NCT03547830</nct_id>
  </id_info>
  <brief_title>Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients</brief_title>
  <official_title>A Clinical Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure in Patients With Chronic Granulomatous Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF
      as additional agents for prevention of graft failure after transplantation in patients with
      chronic granulomatous disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe primary or secondary graft dysfunction is one of major problem in patients with
      Chronic granulomatous disease (CGD). In this study the hypothesis is that the use of
      plerixafor and G-CSF as additional agents in conditioning regimen would offers advantages.
      The effect is based on mobilizing bone marrow stem cells into the peripheral blood and
      blocking CXCR4 chemokine receptors to prevent stem cell homing. Thus, some have hypothesized
      that plerixafor and G-CSF make free stromal space of the bone marrow available for donor stem
      cell engraftment. Moreover, stem cell release probably leads to liberation of host stem cells
      from the anti-apoptotic effects of the BM stroma for the more powerful effect of
      chemotherapy. Thus, the purpose of this study is to evaluate the safety and efficiency of
      myeloablative conditioning with Plerixafor and G-CSF as additional agents for prevention of
      graft failure after stem cell transplantation in patients with chronic granulomatous disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The EFS probability compared with historical control. We mean event as primary (non-engraftment) and secondary (rejection) graft dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>The OS probability compared with historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with full/mixed donor chimerism</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluation of the percentage of patients with the full/mixed donor chimerism (whole blood and CD3+ lineage). In addition, patients will be divided in accordance with % of donors cells: &gt;95%; 50%-95%; 10%-49%; &lt;10%. All data will be compared with historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Transplant related mortality</measure>
    <time_frame>1 year</time_frame>
    <description>The TRM probability compared with historical control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Acute Graft Versus Host Diseases</measure>
    <time_frame>100 days</time_frame>
    <description>Cumulative Incidence of aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Incidence of Plerixafor related toxicity</measure>
    <time_frame>100 days</time_frame>
    <description>severity, features, incidence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Chronic Granulomatous Disease</condition>
  <arm_group>
    <arm_group_label>Plerixafor/G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Plerixafor for Conditioning before HSCT.</description>
    <arm_group_label>Plerixafor/G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gcsf</intervention_name>
    <description>GCSF for Conditioning before HSCT.</description>
    <arm_group_label>Plerixafor/G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged ≥ 1 months and &lt; 25 years Patients diagnosed with CGD eligible for an
        allogeneic transplantation Signed written informed consent

        Exclusion Criteria:

        Lack of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry Balashov, MD</last_name>
    <phone>+79265791817</phone>
    <email>bala8@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svetlana Kozlovskaya, MD</last_name>
    <phone>+79165587891</phone>
    <email>lana.n.kozlovskaya@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanna Shekhovtsova, MD</last_name>
      <phone>4956647078</phone>
      <phone_ext>7538</phone_ext>
      <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
    </contact>
    <contact_backup>
      <last_name>Eugene Pashanov, PhD</last_name>
      <phone>+79262205578</phone>
      <email>e.pashanov@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dmitry Balashov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Gutovskaya E, Kozlovskaya S, Shelikhova L, Novichkova G, Maschan M, Rumiantsev A, Maschan A. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ(+) and CD19(+) Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 Jul;24(7):1432-1440. doi: 10.1016/j.bbmt.2018.03.006. Epub 2018 Mar 14.</citation>
    <PMID>29550630</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic granulomatous disease</keyword>
  <keyword>graft failure</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>plerixafor</keyword>
  <keyword>conditioning regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor octahydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

